416 related articles for article (PubMed ID: 34096197)
1. Microfluidic and Nanofluidic Intracellular Delivery.
Hur J; Chung AJ
Adv Sci (Weinh); 2021 Aug; 8(15):e2004595. PubMed ID: 34096197
[TBL] [Abstract][Full Text] [Related]
2. A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing.
Fajrial AK; He QQ; Wirusanti NI; Slansky JE; Ding X
Theranostics; 2020; 10(12):5532-5549. PubMed ID: 32373229
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
4. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
6. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
8. Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation.
Joo B; Hur J; Kim GB; Yun SG; Chung AJ
ACS Nano; 2021 Aug; 15(8):12888-12898. PubMed ID: 34142817
[TBL] [Abstract][Full Text] [Related]
9. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Kavanagh H; Dunne S; Martin DS; McFadden E; Gallagher L; Schwaber J; Leonard S; O'Dea S
Cytotherapy; 2021 Sep; 23(9):852-860. PubMed ID: 33941482
[TBL] [Abstract][Full Text] [Related]
10. High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing.
Lissandrello CA; Santos JA; Hsi P; Welch M; Mott VL; Kim ES; Chesin J; Haroutunian NJ; Stoddard AG; Czarnecki A; Coppeta JR; Freeman DK; Flusberg DA; Balestrini JL; Tandon V
Sci Rep; 2020 Oct; 10(1):18045. PubMed ID: 33093518
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput and Dosage-Controlled Intracellular Delivery of Large Cargos by an Acoustic-Electric Micro-Vortices Platform.
Aghaamoo M; Chen YH; Li X; Garg N; Jiang R; Yun JT; Lee AP
Adv Sci (Weinh); 2022 Jan; 9(1):e2102021. PubMed ID: 34716688
[TBL] [Abstract][Full Text] [Related]
13. Non-viral strategies for delivering genome editing enzymes.
Li J; Røise JJ; He M; Das R; Murthy N
Adv Drug Deliv Rev; 2021 Jan; 168():99-117. PubMed ID: 32931860
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
15. Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing.
Liu J; Shui SL
J Control Release; 2016 Dec; 244(Pt A):83-97. PubMed ID: 27865852
[TBL] [Abstract][Full Text] [Related]
16. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
[TBL] [Abstract][Full Text] [Related]
18. Microfluidic methods for non-viral gene delivery.
Lai WF
Curr Gene Ther; 2015; 15(1):55-63. PubMed ID: 25545920
[TBL] [Abstract][Full Text] [Related]
19. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
20. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
Wan T; Ping Y
Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
